Differentiating progressive supranuclear palsy from Parkinson's disease by MRI-based dynamic cerebrospinal fluid flow

作者：Fukui Yusuke; Hishikawa Nozomi; Sato Kota; Yunoki Taijun; Kono Syoichiro; Matsuzono Kosuke; Nakano Yumiko; Ohta Yasuyuki; Yamashita Toru; Deguchi Kentaro; Abe Koji^*

来源：Journal of the Neurological Sciences, 2015, 357(1-2): 178-182.

DOI：10.1016/j.jns.2015.07.026

• Cerebrospinal fluid
• Midbrain aqueduct
• Neurodegenerative disorder
• Phase contrast-magnetic resonance imaging
• Parkinson's disease
• Progressive supranuclear palsy

Objective: The purpose of this study was to clarify the difference between PSP and PD from the viewpoint of dynamic cerebrospinal fluid (CSF) flow focusing on the midbrain aqueduct.
Methods: Thirty-three PD patients (mean age 69.2 +/- 7.9) and 35 PSP patients (mean age 70.5 +/- 6.6) were included in this study. CSF flow was calculated by 15 images in an equidistant magnetic resonance imaging (MRI) sequence that was taken throughout a cardiac cycle.
Results: Absolute values of the velocity (time points of 2-6 and 12-15, *p < 0.05), and the width of the CSF velocity (Vheight) (PSP, 5.1 +/- 23 cm/s; PD, 6.0 +/- 1.6 cm/s, p < 0.05) effectively discriminated PSP from PD patients. On the other hand, conventional MRI measurements discriminated well the midbrain aqueduct area (Area) (PSP, 7.7 +/- 2.6 mm(2); PD, 5.4 +/- 1.8 mm(2), p < 0.01). Two cutoff value lines (Vheight: 4.75, Area: 5.77) of the ROC curve analysis established two areas for discriminating PSP from PD.
Conclusion: In the present dynamic CSF flow study, it was newly found that mean velocity of each time point and Vheight showed a more significant decline in PSP than in PD patients, providing a sensitive biomarker for differentiating them. The combination of Vheight and Area could further discriminate PSP from PD patients.

• 出版日期2015-10-15